IBRX profile · all as-reported value updates
ImmunityBio, Inc. (IBRX) as-reported value updates
Descriptive filing record — not investment advice. This page compares two SEC XBRL-filed values for the same fiscal period. It does not state why the values differ and is not a rating, score, or recommendation. See Disclaimer.
Reported values for the same fiscal period can differ between filings for many routine reasons: re-presentation for discontinued operations, adoption of new accounting standards, reclassifications, changes in rounding precision, and amendments. This ledger records that the filed values differ; it does not and cannot determine why. Both filings are linked below so the reader can consult the source.
Ledger table figure
| Metric | FY | Earliest XBRL-filed value | Currently on file | Difference | Difference % | Label | Filing links | Notes |
|---|---|---|---|---|---|---|---|---|
| Stockholders' equity | 2020 | 117,393,000 | -119,808,000 | -237,201,000 | -197.98% | revised comparative figure | 0001564590-21-010945 0001326110-22-000011 | 2 filed observations examined for this concept and period. |
| Revenue | 2019 | 43,000 | 2,202,000 | 2,159,000 | +98.05% | revised comparative figure | 0001564590-20-012816 0001326110-22-000011 | 3 filed observations examined for this concept and period. |
| Liabilities | 2020 | 34,465,000 | 339,871,000 | 305,406,000 | +89.86% | revised comparative figure | 0001564590-21-010945 0001326110-22-000011 | 2 filed observations examined for this concept and period. |
| Cash and cash equivalents | 2019 | 15,508,000 | 75,801,000 | 60,293,000 | +79.54% | revised comparative figure | 0001564590-20-012816 0001326110-22-000011 | 3 filed observations examined for this concept and period. |
| Cash and cash equivalents | 2020 | 11,441,000 | 34,915,000 | 23,474,000 | +67.23% | revised comparative figure | 0001564590-21-010945 0001326110-23-000018 | 3 filed observations examined for this concept and period. |
| Operating cash flow | 2019 | -61,362,000 | -152,109,000 | -90,747,000 | -59.66% | revised comparative figure | 0001564590-20-012816 0001326110-22-000011 | 3 filed observations examined for this concept and period. |
| Operating cash flow | 2020 | -70,453,000 | -171,724,000 | -101,271,000 | -58.97% | revised comparative figure | 0001564590-21-010945 0001326110-23-000018 | 3 filed observations examined for this concept and period. |
| Operating income | 2020 | -91,626,000 | -220,880,000 | -129,254,000 | -58.52% | revised comparative figure | 0001564590-21-010945 0001326110-23-000018 | 3 filed observations examined for this concept and period. |
| Net income | 2020 | -92,383,000 | -221,851,000 | -129,468,000 | -58.36% | revised comparative figure | 0001564590-21-010945 0001326110-23-000018 | 3 filed observations examined for this concept and period. |
| Net income | 2019 | -65,789,000 | -157,777,000 | -91,988,000 | -58.30% | revised comparative figure | 0001564590-20-012816 0001326110-22-000011 | 3 filed observations examined for this concept and period. |
| Operating income | 2019 | -67,807,000 | -156,251,000 | -88,444,000 | -56.60% | revised comparative figure | 0001564590-20-012816 0001326110-22-000011 | 3 filed observations examined for this concept and period. |
| Assets | 2020 | 151,858,000 | 221,381,000 | 69,523,000 | +31.40% | revised comparative figure | 0001564590-21-010945 0001326110-22-000011 | 2 filed observations examined for this concept and period. |